Sign In
Buy GRFS
$7.18
-0.100 (-1.37%)
At Close: Jun 23, 2026
LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
04:00am, Thursday, 04'th Apr 2024
BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
07:53pm, Wednesday, 27'th Mar 2024
NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS).
LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("
LOS ANGELES, CA / ACCESSWIRE / March 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("
LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
06:10pm, Tuesday, 19'th Mar 2024
NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
07:50pm, Monday, 11'th Mar 2024
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS).
Grifols shares drop to 12-year low after new Gotham City Research report
02:03pm, Wednesday, 06'th Mar 2024
Shares in Spanish drugmaker Grifols fell to a 12-year low on Wednesday, following the publication of a new report by Gotham City Research questioning the financial accounts of the Barcelona-based comp
Grifols shares drop 15% after new Gotham City Research report
04:17am, Wednesday, 06'th Mar 2024
Shares in Spanish drugmaker Grifols fell nearly 15% in early trading on Wednesday following the publication of a new report by Gotham City Research questioning the Barcelona-based company's "transpare
Grifols says due diligence done, Shanghai RAAS stake sale to go ahead
03:20am, Friday, 01'st Mar 2024
Grifols' $1.8 billion sale of a 20% stake in Shanghai RAAS will proceed after a due diligence process concluded "satisfactorily", the Spanish drug maker said on Friday.
Grifols hushed on Gotham City short-sell attack during annual results
08:54am, Thursday, 29'th Feb 2024
Spanish pharma group Grifols was silent on the short-selling attack from Gotham City Research in today's annual earnings call. Grifols found itself under scrutiny from US-based Gotham City earlier th
Gotham City Research once again questions Grifols
11:53am, Tuesday, 20'th Feb 2024
Gotham City Research has once again questioned the Spanish pharma group Grifols' ties with a company called Scranton Enterprises. Gotham via its website has posed a series of incendiary questions, f
Gotham City Research renews short-sell attack on Grifols
08:21am, Tuesday, 20'th Feb 2024
Short seller Gotham City Research has renewed its campaign against Spanish pharmaceutical company Grifols, after its responses to Gotham's original hit piece failed to cut the mustard. Gotham's short-
Gotham City issues new report on Grifols, maintains questions over accounting practices
04:05am, Tuesday, 20'th Feb 2024
Short-seller fund Gotham City Research on Tuesday issued a second report on Grifols , maintaining some of its questions over the Spanish pharmaceutical company's accounting practices.
